<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690325</url>
  </required_header>
  <id_info>
    <org_study_id>WSG-AM05</org_study_id>
    <nct_id>NCT01690325</nct_id>
  </id_info>
  <brief_title>Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)</brief_title>
  <official_title>Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GALADON trial is a diagnostic and interventional study in which different molecular&#xD;
      imaging methods as Positon Emission Tomography (PET), different kind of Magnetic Resonance&#xD;
      Imaging - methods (MRI, DWI and DCE-MRI) will be compared with common imaging methods&#xD;
      (mammography, ultrasound) to see if there can detect an early response to a combined&#xD;
      neoadjuvant therapy with bevacizumab and docetaxel in patients with locally advanced breast&#xD;
      cancer. Neoadjuvant chemotherapy (this means patients were treated before the tumor was&#xD;
      removed by surgery) with a drug like trastuzumab (monoclonal antibody) which is target to the&#xD;
      Her2-protein is much more powerful than with chemotherapy alone because it is normalizing the&#xD;
      blood supply and improves tumor delivery of conventional chemotherapy like docetaxel. The&#xD;
      HER2 protein is only available in about 30 % of breast cancer types. bevacizumab is another&#xD;
      humanized monoclonal antibody like trastuzumab but is effective not only in patients with an&#xD;
      positive HER2 status and in combination with trastuzumab it may emphasize the effect in&#xD;
      reduction of tumor growth. Bevacizumab is approved in advanced disease, but no major&#xD;
      neoadjuvant data available so far for primary breast cancer. As the therapy with monoclonal&#xD;
      antibody regimes are expensive and may cause severe side effects predictive factors to select&#xD;
      patients who will benefit from such highly specific drugs before therapy start would be&#xD;
      medically and economically highly valuable. In this study the efficacy of combined&#xD;
      neoadjuvant chemotherapy with bevacizumab, trastuzumab and docetaxel in Arm A and bevacizumab&#xD;
      and docetaxel in Arm B should be evaluated and the predictive impact of different imaging&#xD;
      methods for tumor response should be shown.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment&#xD;
    behind planned schedule and challenges of site performance&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathological complete response (pCR) following neoadjuvant therapy in group A and group B</measure>
    <time_frame>about 18 weeks (start of neoadjuvant chemotherapy until surgery)</time_frame>
    <description>To determine efficacy of cytotoxic-antiangiogenic neoadjuvant therapy in primary breast cancer: bevacizumab+trastuzumab+docetaxel fro group A (HER2 positive) or bevacizumab+docetaxel for group B (HER2 negative) using pathological complete response (pCR) as the primary endpoint.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <arm_group_label>Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <arm_group_label>Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <arm_group_label>Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamid</intervention_name>
    <arm_group_label>Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.</arm_group_label>
    <arm_group_label>Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm A / Arm B&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 65 years&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Operable, locally advanced primary breast cancer (≥ cT2, N0 or N+, M0) histologically&#xD;
             confirmed by core biopsy&#xD;
&#xD;
          -  Histologically confirmed unilateral, solitaire breast cancer&#xD;
&#xD;
          -  Patients who are candidates for neoadjuvant chemotherapy according to AGO guidelines&#xD;
             (www.ago-online.de) with unifocal lesion&#xD;
&#xD;
          -  HER2 positive disease (IHC 3+ and/or FISH positive)or&#xD;
&#xD;
          -  HER2 negative disease (IHC 0/1+, IHC 2+ and/or FISH negative)&#xD;
&#xD;
          -  Baseline LVEF ≥ 55% (measured by MUGA or echocardiography) according to institution&#xD;
             specific norm&#xD;
&#xD;
          -  Informed consent for clinical trial including analysis of predictive imaging tests and&#xD;
             biomarkers&#xD;
&#xD;
          -  Clinically or by imaging (mammogram, MRI or US) assessed breast cancer ≥ 2 cm or&#xD;
             inflammatory breast cancer with bi-dimensional measurable lesion independent of nodal&#xD;
             status&#xD;
&#xD;
          -  Negative pregnancy test (urine or serum) within 7 days prior to registration if&#xD;
             patient is premenopausal with intact reproductive organs and if patient is less than&#xD;
             one year after menopause&#xD;
&#xD;
          -  ECOG Performance status 0-2&#xD;
&#xD;
          -  Adequate organ function for cytotoxic chemotherapy&#xD;
&#xD;
          -  Adequate renal function including Serum creatinine ≤ ULN, Measured or calculated&#xD;
             creatinine clearance &gt; 60 ml/min&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt; 2+. In case of ≥ 2+ proteinuria on dipstick&#xD;
             urinalysis, a 24-hour urine collection must be performed and protein per 24 hours must&#xD;
             be ≤ 1.0 g&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1500 cells/μl, platelet count ≥ 100,000 cells/μl&#xD;
&#xD;
          -  Bilirubin ≤ ULN; ALT or AST ≤ 1.5 x ULN, and alkaline phosphatase &lt; 2.5 x ULN&#xD;
&#xD;
          -  Patients must be available and compliant for treatment and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Arm A / Arm B&#xD;
&#xD;
          -  Evidence of distant metastases by clinical or imaging diagnosis&#xD;
&#xD;
          -  Multifocal primary tumour, defined as histologically confirmed tumour-manifestations&#xD;
             within different quadrants; distance ≥ 4 cm&#xD;
&#xD;
          -  Pre-existing motor or sensory neuropathy of a severity ≥ grade 2 NCI criteria&#xD;
&#xD;
          -  Previous breast cancer&#xD;
&#xD;
          -  Prior malignancy with a disease-free survival of &lt; 5 years&#xD;
&#xD;
          -  Prior malignancy which has not been curatively treated&#xD;
&#xD;
          -  Inflammatory breast cancer without bi-dimensional measurable lesion&#xD;
&#xD;
          -  Prior systemic therapy for cancer&#xD;
&#xD;
          -  Previous therapy with trastuzumab or other anti-HER2 agent (for HER2+ tumors)&#xD;
&#xD;
          -  Previous therapy with bevacizumab or other anti-VEGF agent&#xD;
&#xD;
          -  Patients with immunosuppressive therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women of childbearing potential not using highly effective birth control.&#xD;
&#xD;
          -  Patients with known hypersensitivity reactions to the compounds or incorporated&#xD;
             substances of trastuzumab or its constituents (for HER2+ tumors).&#xD;
&#xD;
          -  Patients with known hypersensitivity reactions to the compounds or incorporated&#xD;
             substances of bevacizumab or its constituents.&#xD;
&#xD;
          -  Invasive malignancy which could affect compliance with the protocol or interpretation&#xD;
             of results.&#xD;
&#xD;
          -  Other serious illness or medical condition including:&#xD;
&#xD;
               -  Known or suspected congestive heart failure (&gt;NYHA I) and/or coronary heart&#xD;
                  disease&#xD;
&#xD;
               -  Angina pectoris requiring antianginal medication&#xD;
&#xD;
               -  Previous history of myocardial infarction&#xD;
&#xD;
               -  Evidence of transmural infarction on ECG&#xD;
&#xD;
               -  Un- or poorly controlled arterial hypertension (i.e. BP &gt;150/100 mmHg under&#xD;
                  treatment with two antihypertensive drugs)&#xD;
&#xD;
               -  Rhythm abnormalities requiring permanent treatment&#xD;
&#xD;
               -  Clinically significant valvular heart disease&#xD;
&#xD;
               -  Patients with dyspnoea at rest due to malignant or other disease or who require&#xD;
                  supportive oxygen therapy&#xD;
&#xD;
               -  Active serious uncontrolled infections&#xD;
&#xD;
               -  Poorly controlled diabetes&#xD;
&#xD;
               -  History of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
               -  History of TIA or CVA&#xD;
&#xD;
               -  History of any arterial thrombotic event within 12 months before randomization&#xD;
&#xD;
          -  Inadequate bone marrow, hepatic and renal functions as evidenced by the following:&#xD;
&#xD;
          -  Neutrophil count of &lt; 1500, platelet count of &lt; 100,000/µL&#xD;
&#xD;
          -  Haemoglobin &lt; 10 g/dL&#xD;
&#xD;
          -  Serum total bilirubin &gt; ULN (except for patients with clearly documented Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  ALT or AST &gt; 1.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 x ULN, serum creatinine &gt; ULN&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy&#xD;
&#xD;
          -  No informed consent for analysis of predictive imaging tests and biomarkers&#xD;
&#xD;
          -  Contraindications against MRI: Cardiac pacemakers, other forms of medical or&#xD;
             biostimulation implants, ferromagnetic foreign bodies or metallic implants (e.g.&#xD;
             surgical protheses, aneurysm clips), implanted insulin pumps, valvular implants,&#xD;
             allergy to contrast agent, renal insufficiency, claustrophobia&#xD;
&#xD;
          -  Active peptic ulcer, incomplete wound healing or unhealed bone fracture&#xD;
&#xD;
          -  Previous thromboembolic events, known hemorrhagic diathesis, coagulopathy with&#xD;
             increased bleeding risk, or treatment with anticoagulants. Current or recent (within&#xD;
             10 days of first dose of bevacizumab) use of acetalic acid (&gt; 325 mg/day) or&#xD;
             clopidogrel (&gt; 75 mg/day)&#xD;
&#xD;
          -  Disease significantly affecting gastrointestinal function, e.g. malabsorption&#xD;
             syndrome, resection of the stomach or small bowel, ulcerative colitis; abdominal&#xD;
             fistula, intra-abdominal abscess within 6 months of enrolment or gastrointestinal&#xD;
             perforation&#xD;
&#xD;
          -  Major surgery within the last 28 days or anticipation of the need for major surgery&#xD;
             during study treatment with bevacizumab. No minor surgeries including insertion of an&#xD;
             indwelling catheter within 24h prior to registration.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs; participation in another clinical&#xD;
             trial with any investigational drug within 30 days prior to study entry&#xD;
&#xD;
          -  Chronic daily treatment with corticosteroids (dose of &gt; 10 mg/day methylprednisolone&#xD;
             equivalent) (excluding inhaled steroids).&#xD;
&#xD;
          -  Patients with a history of hypersensitivity reaction to docetaxel or to drugs&#xD;
             formulated with polysorbate 80&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Harbeck, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Breast Centre, University of Munich, Grosshadern Hospital, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Breast Centre, University of Munich, LMU</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 18, 2012</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Neoadjuvant cytotoxic-antiangiogenic therapy</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

